Tecartus
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
Charting the Path to Heart Health: Advancing Cardiovascular and Metabolic Clinical Trials
Geistek Pharmaceuticals is at the forefront of cardiovascular and metabolic research, driving innovation in the field. We understand the significant impact of cardiovascular and metabolic diseases on global health, and our mission is to discover and develop effective drugs and devices to address these critical medical needs.
With years of experience and a dedicated team of experts, Geistek Pharmaceuticals is committed to conducting comprehensive clinical trials across a range of cardiovascular and metabolic indications. Our focus areas include heart failure, lipid disorders, diabetes, renal insufficiency and transplant, arrhythmia, and rare diseases. Through rigorous research and development, we strive to improve patient outcomes and contribute to the advancement of medical science.
Our approach is rooted in data-driven strategies that optimize timelines and resources throughout the drug development process. We work closely with healthcare professionals, researchers, and regulatory authorities to ensure the highest standards of quality and compliance in our clinical studies.
At Geistek Pharmaceuticals, we recognize the complexity of cardiovascular and metabolic research and the need for specialized expertise. Our multidisciplinary team of professionals, including clinical researchers, scientists, and medical advisors, brings together diverse perspectives to drive innovation and overcome challenges. We collaborate with renowned experts and investigators worldwide to foster a collaborative environment that leads to groundbreaking discoveries.
By leveraging our extensive knowledge and resources, Geistek Pharmaceuticals is dedicated to advancing the understanding of cardiovascular and metabolic diseases. Through our unwavering commitment to excellence in research and development, we aim to improve the lives of patients and contribute to a healthier future for all.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
Cookie | Duración | Descripción |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |